Gina Mazzariello Sells 4,169 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 4,169 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, February 24th. The shares were sold at an average price of $3.15, for a total transaction of $13,132.35. Following the completion of the transaction, the insider now owns 134,921 shares in the company, valued at approximately $425,001.15. This trade represents a 3.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The shares were sold at an average price of $3.49, for a total transaction of $12,836.22.

Amylyx Pharmaceuticals Stock Down 1.3 %

NASDAQ:AMLX opened at $3.16 on Friday. The company has a market capitalization of $216.61 million, a PE ratio of -0.83 and a beta of -0.54. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $19.95. The stock has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $3.81.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Blue Trust Inc. raised its stake in shares of Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after buying an additional 4,883 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Amylyx Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after purchasing an additional 5,104 shares during the last quarter. XTX Topco Ltd raised its stake in Amylyx Pharmaceuticals by 12.0% in the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock valued at $202,000 after purchasing an additional 5,704 shares during the last quarter. Northern Trust Corp raised its stake in Amylyx Pharmaceuticals by 11.8% in the 4th quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after purchasing an additional 11,214 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at about $45,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on AMLX. Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Finally, Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.